(Reuters) - Orexigen Therapeutics Inc said it reached an agreement with U.S. health regulators on the design of a heart-safety trial precondition for the approbate of its vivisection




if (lexico_globals.googleafc.ads.content.length)
{
document.write(lexico_globals.googleafc.ads.contenttop);
document.write(lexico_globals.googleafc.ads.sponsoredlinks);
document.write(lexico_globals.googleafc.ads.content[4]);
document.writ obesity drug. The biopharmaceutical company plans to enroll about 10...

More: - Read the rest here